Analysts predict that Masimo Co. (NASDAQ:MASI) will announce $0.75 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Masimo’s earnings. The lowest EPS estimate is $0.73 and the highest is $0.75. Masimo also posted earnings of $0.75 per share during the same quarter last year. The firm is expected to report its next earnings results on Wednesday, May 1st.
On average, analysts expect that Masimo will report full-year earnings of $3.05 per share for the current year, with EPS estimates ranging from $2.97 to $3.08. For the next fiscal year, analysts expect that the business will report earnings of $3.52 per share, with EPS estimates ranging from $3.43 to $3.60. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Masimo.
Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.10. The firm had revenue of $223.10 million during the quarter, compared to the consensus estimate of $220.96 million. Masimo had a return on equity of 19.53% and a net margin of 22.55%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.72 EPS.
Shares of NASDAQ MASI traded down $3.37 during midday trading on Tuesday, reaching $133.68. 324,462 shares of the stock traded hands, compared to its average volume of 401,626. The company has a market capitalization of $7.11 billion, a P/E ratio of 44.12, a P/E/G ratio of 2.78 and a beta of 1.18. Masimo has a one year low of $83.16 and a one year high of $137.70.
In other Masimo news, insider Jon Coleman sold 2,000 shares of the stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $135.00, for a total value of $270,000.00. Following the sale, the insider now owns 13,201 shares in the company, valued at $1,782,135. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Anand Sampath sold 30,000 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $115.00, for a total value of $3,450,000.00. Following the completion of the sale, the chief operating officer now owns 42,518 shares in the company, valued at approximately $4,889,570. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,877 shares of company stock valued at $5,464,010. 12.60% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its stake in shares of Masimo by 5.1% during the third quarter. Russell Investments Group Ltd. now owns 31,916 shares of the medical equipment provider’s stock valued at $3,973,000 after buying an additional 1,560 shares during the period. ING Groep NV increased its stake in shares of Masimo by 42.7% during the third quarter. ING Groep NV now owns 7,337 shares of the medical equipment provider’s stock valued at $914,000 after buying an additional 2,195 shares during the period. LSV Asset Management purchased a new position in shares of Masimo during the third quarter valued at $1,383,000. SG Americas Securities LLC increased its stake in shares of Masimo by 3.2% during the third quarter. SG Americas Securities LLC now owns 24,081 shares of the medical equipment provider’s stock valued at $2,999,000 after buying an additional 756 shares during the period. Finally, Piedmont Investment Advisors Inc. purchased a new position in shares of Masimo during the third quarter valued at $406,000. Institutional investors and hedge funds own 83.71% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Conference Calls and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.